Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Sep 2019
Price : $35 *
At a glance
- Drugs Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms POP
- Sponsors Biogen
- 12 Sep 2019 Results published in the Biogen Media Release.
- 12 Sep 2019 According to an Biogen Media release, data from this study are being presented at the 35th Congress of the European Committee for Treatment and Research in MS (ECTRIMS) and 24th Annual Conference of Rehabilitation in MS.
- 12 Oct 2018 Interim results (n=963; data cut off Sep 2017) presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis